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Abstract
BACKGROUND—Although obesity is an independent risk factor for heart failure (HF), once HF 
is established, obesity is associated with lower mortality. It is unclear if the weight loss due to 
advanced HF leads to this paradoxical finding.
OBJECTIVES—We sought to evaluate the prognostic impact of pre-morbid obesity in patients 
with HF.
METHODS—In the Atherosclerosis Risk in Communities (ARIC) study, we used body mass 
index (BMI) measured ≥6 months before incident HF (pre-morbid BMI) to evaluate the 
association of overweight (BMI 25 to <30 kg/m2) and obesity (≥30 kg/m2) compared to normal 
BMI (18.5 to <25 kg/m2) with mortality after incident HF.
RESULTS—Among 1,487 patients with incident HF, 35% were overweight and 47% were obese 
by pre-morbid BMI measured 4.3 ± 3.1 years before HF diagnosis. Over 10-year follow-up after 
incident HF, 43% of patients died. After adjustment for demographics and comorbidities, being 
premorbidly overweight (hazard ratio [HR]: 0.72; 95% confidence interval [CI[]: 0.58 to 0.90; p = 
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0.004) or obese (HR: 0.70; 95% CI: 0.56 to 0.87; p = 0.001) had a protective association with 
survival compared to normal BMI. The protective effect of overweight and obesity was consistent 
across subgroups based on a history of cancer, smoking, and diabetes.
CONCLUSIONS—Our results, for the first time, demonstrate that individuals who were 
overweight or obese before HF development have lower mortality once they have HF compared 
with normal BMI individuals. Thus, weight loss due to advanced HF may not completely explain 
the protective effect of higher BMI in HF patients.
Keywords
Obesity paradox; outcomes; overweight; premorbid
INTRODUCTION
Obesity has reached epidemic proportions in the United States, with more than two-thirds of 
adults being either overweight or obese (1). Obesity is linked to the development of 
cardiovascular diseases including atherosclerosis and hypertension (2). Although 
independently associated with the development of heart failure (HF) (3,4), obesity also has 
been shown to be associated with better survival once HF is established (5,6–9), often 
referred to as the “obesity paradox” (10).
One plausible explanation for this paradox: HF patients who gain or preserve their weight 
may represent a noncatabolic subgroup of HF patients with different neurohormonal, 
inflammatory, and metabolic profiles compared with HF patients who lose weight. The 
known protective effects of the ability to maintain or gain weight in other chronic diseases 
or catabolic states such as the acquired immunodeficiency syndrome, renal disease, and 
cancer lend support to this concept (11). Therefore, spontaneous weight loss (cachexia in 
extreme cases) after the development of HF may characterize a sicker group of patients with 
HF and, thus, may be associated with greater mortality (12).
However, it is not clear if weight loss after development of HF is the sole contributor to the 
obesity paradox or whether additional mechanisms, such as pre-existing obesity with 
possibly greater metabolic reserve prior to HF onset, contribute to the better survival of HF 
patients. Therefore, we examined the relationship of premorbid obesity (i.e., prior to incident 
HF) with mortality following incident HF. To our knowledge, this is the first study to 




The ARIC (Atherosclerosis Risk in Communities) study is an ongoing community-based 
cohort study of 15,792 patients, comprised mostly of Caucasian and African-American men 
and women, aged 45 to 64 years at baseline (1987 to 1989) and sampled from 4 U.S. 
communities: Forsyth County, North Carolina; suburbs of Minneapolis, Minnesota; 
Washington County, Maryland; and Jackson, Mississippi (13). The institutional review 
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boards from each site approved the ARIC study and all participants provided written 
informed consent. Standardized physical examinations and interviewer-administered 
questionnaires were conducted at baseline (visit 1) and at approximately 3-year follow-up 
intervals (visit 4: 1996 to 1998). Participant follow-up through annual telephone interviews, 
hospitalization, and vital status is ongoing. Individuals with missing anthropometry (n = 33), 
prevalent HF at the first study visit (n = 751), and those with missing data to determine 
prevalent HF at baseline (n = 289) were excluded (14). Participants with race not classified 
as white or black (n = 48), and blacks not from Jackson or Forsyth County (n = 120) were 
excluded due to their limited numbers.
ASCERTAINMENT OF HF CASES AND FOLLOW-UP
To determine HF cases, the following methods were used: 1) annual interviews of 
participants regarding interim hospitalizations (response rate: 93% to 96%); 2) review of 
discharge lists from local hospitals; and 3) survey of health department death certificate files 
and the national death index. Incident HF was defined as the first episode of either a 
hospitalization that included an International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) discharge diagnosis code for HF beginning with “428” 
(i.e., 428.0 to 428.9) in any position or a death certificate ICD-9 code beginning with “428” 
or ICD-10 code “I50” (HF or I50.0 to I50.9) in any position. For this study, incident HF was 
determined until December 31, 2004, date of last contact, or death (14).
ANTHROPOMETRY
Participants presented for each study visit after an overnight fast and measurements were 
taken in standard scrub attire. Weight was measured using a scale that was zeroed daily and 
calibrated quarterly. Premorbid body mass index (BMI) was defined as a BMI measurement 
from a study visit that occurred 6 months or more prior to the incident date of HF. Patients 
with HF were categorized by the premorbid BMI into normal (18.5 to <25 kg/m2), 
overweight (25 to <30 kg/m2), and obese (≥30 kg/m2) groups (15). Patients in the 
underweight category (BMI <18.5 kg/m2; n = 32) were excluded from this analysis because 
of small numbers and possible other pre-existing comorbidities that may have led to a 
cachectic state.
BASELINE COVARIATES
Ascertainment of demographics and comorbidities at each study visit has been described in 
detail previously (13). Age was assessed at the time of incident HF and sex, race, and 
education level were obtained from the baseline ARIC visit with interviewer-administered 
questionnaires. Comorbidities, including hypertension, history of myocardial infarction 
(MI), coronary heart disease (CHD), diabetes mellitus (DM) and stroke were assessed as 
present if these conditions were documented at any of the pre-HF study visits. History of MI 
was defined as self-report of physician-diagnosed MI or electrocardiographic diagnosis of 
silent MI. CHD was defined as history of MI, coronary revascularization, or coronary artery 
bypass surgery. Hypertension was defined by either a systolic blood pressure (SBP) ≥140 
mm Hg or diastolic blood pressure ≥90 mm Hg measured with random-zero mercury 
manometers or recent anti-hypertensive medication use. Presence of DM was defined as 
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either self-reported physician-diagnosed diabetes, recent diabetes medication use, or a blood 
glucose ≥126 mg/dl fasting or ≥200 mg/dl nonfasting (13).
Alcohol use, SBP, serum creatinine, total serum cholesterol, and insurance status also were 
collected from the pre-HF ARIC study visit. Patients were defined as smokers if the 
participants reported a history of current smoking at the pre-HF ARIC study visit. A history 
of cancer reported at any study visit prior to or including the pre-HF visit was used to define 
a positive history of cancer. Data for any variables with missing values at the pre-HF visit 
utilized available data from prior study visits. Renal function was quantified by the 
estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease 
equation (16).
STATISTICAL ANALYSIS
Data are shown as mean ± standard deviation and percentages. Missing values were found to 
be less than 0.8%. Univariate differences among the 3 BMI groups were examined using the 
chi-square test for categorical variables and the analysis of variance (ANOVA) test for 
continuous variables. To assess the prognostic significance of premorbid BMI in HF 
patients, the endpoint was time to all-cause mortality after incident HF. We performed 
Kaplan-Meier survival analysis and used the log-rank test to compare time to death after 
incident HF among the 3 BMI groups. Because the number of patients after 10-year follow-
up from the incident HF episode was small, we censored the follow-up after incident HF at 
10 years. Cox proportional hazard models were used to examine the relationship between 
the BMI group and survival. Due to violation of the proportionality assumption, a time-
dependent term, the product of BMI group and log time was added to the model to represent 
the nonhomogeneity of the hazard (17). The adjusted model was fitted by adding age, sex, 
race, history of MI, hypertension, CHD, DM, stroke, cancer, alcohol use, smoking status, 
insurance, education level, SBP, and eGFR as covariates. Due to concerns relating to 
smoking and history of cancer and their association with BMI status and mortality, as well 
as the fact that statistical adjustments may not be sufficient to control for duration, intensity, 
or timing of smoking exposure, we also conducted subgroup analyses by the presence or 
absence of a history of smoking and cancer. Similarly, due to prior studies demonstrating a 
possible differential effect of obesity and overweight on mortality in HF patients based on 
diabetic status, we also performed subgroup analysis by the presence or absence of DM 
(5,7,18–22). P values < 0.05 were considered to be significant. All analyses were performed 
using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
The study cohort consisted of 1.487 HF patients categorized as normal, overweight, or obese 
based on BMI obtained at least 6 months prior to incident HF. Overall, 54% of the HF 
patients were male and 66% were white; they averaged 67 years of age at the time of 
diagnosis. Premorbidly, the majority of patients were either overweight (35%) or obese 
(47%). The premorbid BMI was measured 4.3 ± 3.1 years before the HF diagnosis at the last 
ARIC study visit that occurred at least 6 months prior to incident HF. Baseline 
characteristics of patients with incident HF by the 3 premorbid BMI groups are shown in 
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Table 1. Compared to HF patients with normal BMI, obese HF patients were younger, more 
often African American, and less likely to have health insurance, and attained a lower 
education level. Overweight and obese HF patients had higher prevalence of comorbidities 
such as DM and hypertension, as well as higher SBP. Smoking was associated with lower 
BMI. There was no significant difference in the time period of measurement of BMI prior to 
incident HF among the 3 BMI categories.
Over a follow-up period of 10 years, a total of 43% of all HF patients died. The Central 
Illustration shows the Kaplan-Meier survival curves by BMI group over 10-year follow-up 
after incident HF. The overweight and obese groups had better survival compared with the 
normal-weight group. Over time, the survival curve for the obese patients appeared to 
converge towards the other groups, and crossed over the overweight group at ~7.5 years 
follow-up. On the other hand, the curves for overweight appeared to remain parallel to the 
normal-weight group. Compared to normal BMI, overweight (hazard ratio [HR]: 0.77; 95% 
confidence interval [CI]: 0.62 to 0.96) and obesity (HR: 0.75; 95% CI: 0.61 to 0.91) were 
associated with improved survival. As expected from the Kaplan-Meier curves, the 
interaction between BMI group and log time was not significant for the overweight group (p 
= 0.74), but was significant for the obese group (p = 0.02). The interaction terms were 
therefore included in the models. As shown in Table 2, even after adjusting for covariates, 
premorbid overweight and obesity remained independent predictors of improved survival 
compared with normal BMI.
A sensitivity analysis was performed after excluding patients with a presentation of fatal 
incident HF. Again, the overweight (adjusted HR: 0.72; 95% CI: 0.57 to 0.90; interaction 
with log time p = 0.37) and obese (adjusted HR: 0.69; 95% CI: 0.56 to 0.86; interaction with 
log time p < 0.001) HF patients had significantly better survival compared with normal BMI 
HF patients.
Subgroup analyses were conducted in HF patients based on smoking, history of cancer, and 
the presence or absence of diabetes (Figure 1). The beneficial trends associated with 
premorbid overweight and obesity compared with normal weight, similar to those observed 
in the overall cohort, were noted in all subgroups, although not all differences reached 
statistical significance.
DISCUSSION
This study demonstrates that among individuals who develop HF in the community, the 
majority are premorbidly overweight or obese. Additionally, for the first time, we have 
shown that patients who are overweight or obese before incident HF have better survival 
after they develop HF compared with patients with normal BMI. This association is 
independent of the patients’ demographic profile and comorbidities. Furthermore, this trend 
occurred irrespective of smoking status, history of cancer, or diabetes.
Our findings of an association between a higher premorbid BMI and improved survival 
following incident HF could suggest that obese patients have a higher metabolic reserve 
compared with normal-weight patients, providing them with a survival advantage when 
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cardiac cachexia ensues after HF development. Several studies have demonstrated an 
obesity paradox in patients with chronic and acute decompensated HF, i.e., a survival 
advantage of higher BMI measured in patients with established HF (5,7–9, 18–22). It must 
be noted that none of the previous studies demonstrating the obesity paradox in HF used the 
BMI (or BMI-equivalent variable) prior to development of HF. Moreover, very few studies 
had a follow-up >5 years (23,24). Because prior studies used the BMI of patients with 
established HF, they were unable to distinguish between the effect of weight loss between 
the time of development of HF and the BMI measurement as a marker of more advanced HF 
versus the possible survival advantage of pre-existing obesity or overweight. Our study goes 
a major step further than prior studies by demonstrating that higher premorbid BMI is 
independently associated with a long-term survival advantage over a long (10-year) follow-
up period.
Several proposed mechanisms could contribute to this apparent obesity paradox, including 
the fact that HF is a catabolic state leading to cachexia, and obese and overweight patients 
may have better outcomes as they have higher metabolic reserves (12,25). Another 
hypothesis is that obesity alters the natural history of HF through neurohumoral pathways. 
Higher levels of serum lipoproteins may neutralize bacterial lipopolysaccharides and thus 
attenuate the detrimental cytokine response in HF (26–29). Adipose tissue may produce 
higher levels of soluble tumor necrosis factor (TNF) receptors that serve as a reservoir for 
harmful circulating TNF (30). Levels of circulating stem cells are also higher in obese 
individuals (31). Furthermore, obese patients have decreased adiponectin levels and an 
attenuated renin-angiotensin system and catecholamine response, both of which are 
associated with improved HF survival (26,32).
Another possible explanation is that obese or overweight individuals may present with and 
be diagnosed with HF at an earlier stage due to symptoms exacerbated by excess body 
weight, such as dyspnea and edema (that is, the obesity paradox may represent a lead-time 
bias). Furthermore, obese patients have a higher prevalence of comorbidities such as 
hypertension and DM, as supported by our study, and may represent a higher-risk population 
for HF. Another possibility: the higher prevalence of hypertension, as well as higher blood 
pressures, in the overweight and obese patients may allow greater up-titration of disease-
modifying HF therapies. It is interesting to note that the protective effect of obesity was 
greatest during the initial years (Central Illustration) with significant interaction between 
BMI group and time, suggesting perhaps that during the later years, the complications of 
obesity-associated comorbidities catch up and lead to a greater decline in survival. This 
finding would also be expected if a lead-time bias is contributing with an earlier presentation 
with HF due to obesity-enhanced symptoms. Unlike our analysis, most studies that have 
examined the obesity paradox in patients with established HF have had shorter follow-up 
periods, usually <5 years. In contrast, the protective effect of being overweight did not 
appear to decrease over time. Although a history of cancer and smoking are associated with 
lower BMI and higher mortality, perhaps confounding the analyses of BMI and survival, our 
subgroup analyses did suggest that the observed results were independent of smoking or 
cancer status.
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Previous studies that have evaluated the association between obesity and cardiovascular 
outcomes have used various indices of obesity, including BMI, waist circumference and 
waist-hip ratio, and percent body fat (22,23). Whereas, waist-hip ratio and waist 
circumference are better predictors of central obesity, BMI reflects generalized obesity 
(34,35). Based on previous analyses conducted on the ARIC cohort (14), which had 
confirmed that obesity and overweight are independent risk factors for developing HF, the 
degree and pattern of relationships for the development of HF were comparable for all 3 
indices of obesity. Also, because most previous studies that have evaluated the association 
between obesity and cardiovascular outcomes have used BMI, we used BMI as the index of 
obesity in our study.
The recent HF guidelines from the American College of Cardiology and American Heart 
Association do not specifically recommend weight reduction in obese patients with HF 
based on the lack of data demonstrating a beneficial effect in this population (36). Although 
our study suggests that patients who are overweight/obese before the development of HF 
have better survival compared with patients of normal weight, it does not answer whether 
targeted weight reduction in obese patients with HF is beneficial or not. Only a randomized 
controlled trial of targeted weight reduction in obese patients with HF could help resolve 
that question.
STUDY LIMITATIONS
Our study has inherent limitations associated with an observational cohort study, including 
those of possible residual confounding from unmeasured covariates. In addition, 
identification of the cases relied on ICD–9 codes; only hospitalized HF and incident fatal HF 
were included because we lacked consistent data on outpatient HF. However, validation of 
HF hospitalizations in an ARIC community surveillance study in 2005 has shown that the 
sensitivity and positive predictive value of ICD code 428.x in any position for HF classified 
by subsequent medical record review by ARIC criteria were 0.95 and 0.77, respectively, for 
combined acute decompensated HF and chronic HF (in comparison to 0.83 and 0.78, 
respectively, by Framingham criteria) (37). Also, the fact that there was a long time period 
between measurement of BMI and incident HF (average 4.2 years) makes it unlikely that our 
cohort included HF cases in whom weight loss as a result of HF would have occurred.
Furthermore, community surveillance reports have indicated that 74% of outpatient HF 
cases are hospitalized within 1.7 years (38). Since a diagnosis of HF in obese individuals 
may be less specific than that in normal-weight individuals, there is a possibility of 
differential misclassification bias. Also, we were unable to adjust for level of fitness, which 
has been shown to modify the association of BMI with prognosis in HF (39,40). Fatal initial 
HF episodes were determined from death certificates, which may overestimate or 
underestimate the true number of cases. We did not have a record of medical therapies 
instituted following incident HF and were unable to adjust for potential differences in 
therapy by BMI status. Additionally, the type of HF (HF with preserved or reduced ejection 
fraction) was not known.
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The majority of patients with incident HF in the community have pre-existing overweight or 
obesity. Once the overweight/obese patients develop HF, they have lower mortality 
compared with HF patients with prior normal BMI. These results suggest that a significant 
component of the obesity paradox is driven by premorbid obesity and it is, therefore, 
unlikely that cardiac cachexia due to advanced HF is the only mechanism contributing to the 
observed obesity paradox in established HF. Future studies are needed to confirm our 
observations in other cohorts.
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COMPETENCY IN MEDICAL KNOWLEDGE
Although higher body mass index is associated with an increased risk of developing 
clinical heart failure (HF), patients with HF who are overweight or obese have better 
survival rates than those with normal weight. This obesity paradox also applies to 
patients who were overweight or obese before incident HF hospitalization, suggesting 
that the paradox is not entirely accounted for by weight loss or cardiac cachexia due to 
HF.
TRANSLATIONAL OUTLOOK
Further research is needed to understand the mechanisms responsible for the protective 
effect of premorbid overweight and obesity and the effect of intentional weight loss on 
clinical outcomes in patients with HF.
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FIGURE 1. Adjusted Risk of Mortality Associated with BMI Category
The adjusted hazard ratios (HR) and 95% confidence intervals (CI) for mortality risk for the 
obese and overweight groups compared to the normal-weight group (reference group; HR = 
1) are shown on a logarithmic scale for the overall cohort, and for the subgroups stratified by 
smoking, cancer, and diabetes. The results are consistent across all subgroups.
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CENTRAL ILLUSTRATION. Kaplan-Meier Survival Curves in HF Patients by Pre-HF BMI 
Categories
Survival after the development of heart failure (HF) differed significantly among body mass 
index (BMI) groups defined by pre-HF BMI. The overweight and obese patients had better 
survival compared with the normal-weight group.
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TABLE 2
Hazard Ratios for All-cause Mortality after Incident HF
BMI Category Incident HF Deaths over 10 Years Adjusted Hazard Ratio (95% CI)† p Value††
Normal 274 141 (51) 1
Overweight 519 232 (45) 0.72 (0.58 – 0.90) 0.99
Obese 695 265 (38) 0.70 (0.56 – 0.87) 0.02
†
The models included the following covariates in addition to BMI and time-dependent term of group*log (time in years): age; sex; race; education 
level; health insurance; diabetes; hypertension; history of MI, CAD, or stroke; cancer; smoking; alcohol use; systolic blood pressure; total 
cholesterol; and estimated GFR.
††
For BMI group*log time interaction
Values are n or n (%).
BMI = body mass index; CI = confidence interval; other abbreviations as in Table 1.
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